Markets

ORIC Pharmaceuticals Announces Agreement With Cancer Research UK To Advance Potential CIP2A-Targeted Therapy Into Clinical Development

Oct 5, 2026 · 04:02 PM ET· updated 1h ago

ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable targetCancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2

Why It Matters

ORIC found a partner to test a new cancer medicine they created. This means the company gets help paying for early testing without spending their own money.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ORIC12.47

+0.27 (+2.17%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.